(Q51110220)

30 March 2018

meta-analysis

0 references

title

Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing. (English)

1 reference

30 March 2018

1 reference

1 reference

2

1 reference

30 March 2018

Andrew J. McLachlan

5

1 reference

30 March 2018

author name string

Michael J Dolton

1

1 reference

30 March 2018

Johanna Weiss

3

1 reference

30 March 2018

John E Ray

4

1 reference

30 March 2018

language of work or name

English

0 references

publication date

18 February 2014

1 reference

30 March 2018

Journal of Antimicrobial Chemotherapy

number of pages

9

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

30 March 2018

volume

69

1 reference

30 March 2018

issue

6

1 reference

30 March 2018

page(s)

1633-1641

1 reference

30 March 2018

Voriconazole: a new triazole antifungal agent

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU031

Pharmacokinetic/pharmacodynamic profile of voriconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU031

Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU031

Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU031

Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU031

Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU031

Voriconazole therapeutic drug monitoring.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU031

Voriconazole concentrations and outcome of invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU031

Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU031

Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU031

The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU031

Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU031

Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A limited sampling strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU031

Steady-state pharmacokinetics and metabolism of voriconazole in patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU031

Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU031

PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU031

Performance of methods for handling missing categorical covariate data in population pharmacokinetic analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU031

CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU031

Clinical importance of the CYP2C19*17 variant allele for voriconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU031

Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU031

Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU031

Population pharmacokinetics of voriconazole in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU031

Voriconazole serum concentrations in obese and overweight immunocompromised patients: a retrospective review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU031

Steady-state plasma pharmacokinetics of oral voriconazole in obese adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU031

Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU031

Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU031

Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU031

Complexity of interactions between voriconazole and antiretroviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU031

Population pharmacokinetic evaluation with external validation and Bayesian estimator of voriconazole in liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU031

Software for dosage individualization of voriconazole for immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU031

Potent cytochrome P450 2C19 genotype–related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU031

21 January 2018

Identifiers

DOI

10.1093/JAC/DKU031

1 reference

30 March 2018

PubMed ID

24554646

1 reference

30 March 2018